NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a clinical-stage biopharmaceutical company, announced today that an article in Ophthalmology Times has highlighted the “novel advances” provided by NovaBay’s new i-Lid Cleanser. The product, said the June 1 article, is “a safe and effective alternative for cleansing the lids, lashes, and periocular skin of debris and microorganisms, which can cause irritation, inflammation, and ocular surface disease.”
“Ophthalmology Times is a trusted source of information on cutting-edge advancements in eye care,” said Dr. Ron Najafi, CEO of NovaBay. “We’re pleased that it has recognized the benefits of our new product.”
As the article explains, i-Lid Cleanser contains a pure, stable version of hypochlorous acid to keep it antimicrobial. Hypochlorous Acid is a substance produced by the immune system as a first defense against microbial invaders. Lab tests show i-Lid Cleanser kills the bacteria that grow on eyelids. Those bacteria cause a very common condition called blepharitis, which causes swelling, redness, irritation and a crusty build-up on patient’s eye lids that may last for months or even years. Moreover, the lab tests show, i-Lid Cleanser also neutralizes the toxins that bacteria produce, which contribute to other eye conditions like dry eye syndrome related to meibomian gland dysfunction.
At the University Of Illinois College Of Medicine at Peoria, Dr. Steven J. Lichtenstein, associate professor of clinical surgery and pediatrics and Medical Director of Pediatric Ophthalmology at the Children’s Hospital of Illinois, used to clean and treat the eyes of children suffering from chronic blepharitis with diluted baby shampoo, antibiotics and steroids. Now, he explained in the article, he uses i-Lid Cleanser instead. “It seems to provide better results while eliminating or reducing the need for antibiotics and steroids along with their associated costs and concerns,” he said.
Kathryn Najafi-Tagol, MD, Ophthalmologist and Surgeon, founder of the Eye Institute of Marin in San Rafael, Calif, and the developer of i-Lid Cleanser, said in the article that she’s also seen excellent results. “My patients have been very pleased with the product, enjoying not only its efficacy as a cleanser but also what many describe as a refreshing feeling.”
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company focused on addressing the unmet therapeutic needs of the global, topical anti-infective market.
This release contains forward-looking statements and opinions, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the general effectiveness of NovaBay’s products and the potential uses by physicians. The words are intended to identify these forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in development, clinical trial, regulatory approval, production and marketing of the company’s product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company’s intellectual property or trade secrets, the company’s ability to obtain additional financing as necessary and unanticipated research and development and other costs. Other risks relating to NovaBay and Aganocide compounds, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website
NovaBay Pharmaceuticals Contacts
Thomas J. Paulson
Chief Financial Officer
Contact Thomas Paulson